322 related articles for article (PubMed ID: 33442793)
1. Venetoclax and donor lymphocyte infusion for early relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. A retrospective multicenter trial.
Amit O; On YB; Perez G; Shargian-Alon L; Yeshurun M; Ram R
Ann Hematol; 2021 Mar; 100(3):817-824. PubMed ID: 33442793
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation.
Zhao P; Ni M; Ma D; Fang Q; Zhang Y; Li Y; Huang Y; Chen Y; Chai X; Zhan Y; Li Y; Kang Q; Zhao M; Liu M; Zhang F; Huang S; Wen S; Deng B; Wang J
Ann Hematol; 2022 Jan; 101(1):119-130. PubMed ID: 34568973
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study.
Ram R; Amit O; Zuckerman T; Gurion R; Raanani P; Bar-On Y; Avivi I; Wolach O
Ann Hematol; 2019 Aug; 98(8):1927-1932. PubMed ID: 31187237
[TBL] [Abstract][Full Text] [Related]
4. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
[TBL] [Abstract][Full Text] [Related]
9. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.
Joshi M; Cook J; McCullough K; Nanaa A; Gangat N; Foran JM; Murthy HS; Kharfan-Dabaja MA; Sproat L; Palmer J; Pardanani A; Tefferi A; Begna K; Elliot M; Al-Kali A; Patnaik M; Shah MV; Hogan WJ; Litzow MR; Alkhateeb HB
Blood Cancer J; 2021 Mar; 11(3):49. PubMed ID: 33664234
[No Abstract] [Full Text] [Related]
10. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
[TBL] [Abstract][Full Text] [Related]
11. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
Byrne M; Danielson N; Sengsayadeth S; Rasche A; Culos K; Gatwood K; Wyatt H; Chinratanalab W; Dholaria B; Ferrell PB; Fogo K; Goodman S; Jagasia M; Jayani R; Kassim A; Mohan SR; Savani BN; Strickland SA; Engelhardt BG; Savona M
Am J Hematol; 2020 Sep; 95(9):1006-1014. PubMed ID: 32390196
[TBL] [Abstract][Full Text] [Related]
12. Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI.
Kumar AJ; Vassilev P; Loren AW; Luger SM; Reshef R; Gill S; Smith J; Goldstein SC; Hexner E; Stadtmauer EA; Porter D; Frey NV
Am J Hematol; 2016 Jun; 91(4):426-9. PubMed ID: 26820493
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant.
Ionescu F; David JC; Ravichandran A; Sallman DA; Sweet K; Komrokji RS; Chan O; Kuykendall A; Padron E; Faramand R; Bejanyan N; Khimani F; Elmariah H; Pidala J; Mishra A; Perez L; Nishihori T; Lancet JE
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):400-406. PubMed ID: 38429222
[TBL] [Abstract][Full Text] [Related]
14. The benefit of chronic graft-versus-host disease in patients with acute myeloid leukemia relapsed after allogeneic stem cell transplantation.
Wang Z; Yin C; Zhang W; Tang W; Song X; Hu X; Ni X; Qiu H; Yang J; Hu J; Wang J
Ann Hematol; 2019 Jul; 98(7):1765-1773. PubMed ID: 30993416
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.
Ghobadi A; Choi J; Fiala MA; Fletcher T; Liu J; Eissenberg LG; Abboud C; Cashen A; Vij R; Schroeder MA; Pusic I; Stockerl-Goldstein K; Jacoby M; Uy G; DiPersio J; Westervelt P
Leuk Res; 2016 Oct; 49():1-6. PubMed ID: 27505705
[TBL] [Abstract][Full Text] [Related]
16. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249
[TBL] [Abstract][Full Text] [Related]
18. Interferon-α salvage treatment is effective for patients with acute leukemia/myelodysplastic syndrome with unsatisfactory response to minimal residual disease-directed donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation.
Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Han W; Wang F; Wang J; Liu K; Huang X
Front Med; 2019 Apr; 13(2):238-249. PubMed ID: 29656333
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
20. Real world results of venetoclax combined with hypomethylating agents in relapsed/refractory AML.
Ucar MA; Ozet G; Koyuncu MB; Sonmez M; Akidan O; Ayli M; Yildirim M; Pehlivan M; Akkurd DM; Sahin H; Guvenc B; Okan V; Tiftik EN; Akdeniz A; Dincyurek HD; Gunes AK; Dagdas S; Acar HI; Ucar HK; Tombak A
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6557-6565. PubMed ID: 34787859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
